Scleroderma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Crp., Johnson & Johnson, Prometic Life Sciences

Posted on
by

Scleroderma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Crp., Johnson & Johnson, Prometic Life Sciences
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Scleroderma pipeline constitutes 45+ key companies continuously working towards developing 50+ Scleroderma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Scleroderma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.

 

The Scleroderma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Scleroderma Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Scleroderma treatment therapies with a considerable amount of success over the years. 

  • Scleroderma companies working in the treatment market are Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Scleroderma treatment 

  • Emerging Scleroderma therapies in the different phases of clinical trials are- RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others are expected to have a significant impact on the Scleroderma market in the coming years.   

  • In December 2023, The Scleroderma Research Foundation (SRF), the largest US non-profit funder of scleroderma research, announced that the FDA has approved its Investigational New Drug (IND) application to start the CONQUEST clinical trial and enroll patients. Sanofi and Boehringer Ingelheim, the first pharma partners in this protocol, will each contribute an experimental drug for scleroderma treatment. The trial will evaluate amlitelimab from Sanofi, a monoclonal antibody targeting OX40-Ligand, and BI-1015550 from Boehringer Ingelheim, an oral PDE-4B inhibitor, for safety and efficacy in scleroderma patients with interstitial lung disease (SSc-ILD). Both drugs have shown promise in previous non-scleroderma trials.

  • In November 2024, Following positive Phase II trial results for scleroderma, Certa Therapeutics plans to initiate a pivotal trial with FT011 in late 2024. The company intends to discuss the trial design and related development plans with the US Food and Drug Administration (FDA) in early 2024, and will also seek complementary scientific advice from the European Medicines Agency (EMA) in mid-2024.

 

Scleroderma Overview

Scleroderma, also known as systemic sclerosis, is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues. It can affect the skin, blood vessels, muscles, and internal organs.

 

Get a Free Sample PDF Report to know more about Scleroderma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/scleroderma-pipeline-insight

 

Emerging Scleroderma Drugs Under Different Phases of Clinical Development Include:

  • RO7303509: Genentech

  • AM 1476: AnaMar AB

  • MK-2225: Acceleron Pharma

  • BI 685509: Boehringer Ingelheim

  • Brentuximab: Vedotin Seagen

  • HZN-825: Horizon Pharmaceuticals

  • MT-0551: Mitsubishi Tanabe PharmaCorporation

 

Scleroderma Route of Administration

Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Scleroderma Molecule Type

Scleroderma Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Scleroderma Pipeline Therapeutics Assessment

  • Scleroderma Assessment by Product Type

  • Scleroderma By Stage and Product Type

  • Scleroderma Assessment by Route of Administration

  • Scleroderma By Stage and Route of Administration

  • Scleroderma Assessment by Molecule Type

  • Scleroderma by Stage and Molecule Type

 

DelveInsight’s Scleroderma Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Scleroderma product details are provided in the report. Download the Scleroderma pipeline report to learn more about the emerging Scleroderma therapies

 

Some of the key companies in the Scleroderma Therapeutics Market include:

Key companies developing therapies for Scleroderma are – Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC (GSK), Novartis AG, and others.

 

Scleroderma Pipeline Analysis:

The Scleroderma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.

  • Scleroderma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Scleroderma drugs and therapies

 

Scleroderma Pipeline Market Drivers

  • Pharmaceutical and Biotechnology Industries striving on the development of new therapy, increased Awareness among people related to the disease are some of the important factors that are fueling the Scleroderma Market.

 

Scleroderma Pipeline Market Barriers

  • However, higher healthcare cost, adverse effects associated with the drugs and other factors are creating obstacles in the Scleroderma Market growth.

 

Scope of Scleroderma Pipeline Drug Insight    

  • Coverage: Global

  • Key Scleroderma Companies: Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others

  • Key Scleroderma Therapies: RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others

  • Scleroderma Therapeutic Assessment: Scleroderma current marketed and Scleroderma emerging therapies

  • Scleroderma Market Dynamics: Scleroderma market drivers and Scleroderma market barriers 

 

Request for Sample PDF Report for Scleroderma Pipeline Assessment and clinical trials

 

Table of Contents 

1. Scleroderma Report Introduction

2. Scleroderma Executive Summary

3. Scleroderma Overview

4. Scleroderma- Analytical Perspective In-depth Commercial Assessment

5. Scleroderma Pipeline Therapeutics

6. Scleroderma Late Stage Products (Phase II/III)

7. Scleroderma Mid Stage Products (Phase II)

8. Scleroderma Early Stage Products (Phase I)

9. Scleroderma Preclinical Stage Products

10. Scleroderma Therapeutics Assessment

11. Scleroderma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Scleroderma Key Companies

14. Scleroderma Key Products

15. Scleroderma Unmet Needs

16 . Scleroderma Market Drivers and Barriers

17. Scleroderma Future Perspectives and Conclusion

18. Scleroderma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/